JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis

  • 0Department of Urology, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China.
International Journal of Medical Sciences +

|

September 23, 2024

|

September 23, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Cyclin-dependent kinase 6 (CDK6) is a potential prognostic marker in bladder cancer. High CDK6 expression indicates poor prognosis and reduced response to immunotherapy.

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Research

Background

  • Cyclin-dependent kinase 6 (CDK6) is implicated in tumor progression and metastasis.
  • The precise molecular mechanisms and prognostic significance of CDK6 in bladder cancer remain largely undetermined.

Purpose Of The Study

  • To investigate the role of CDK6 in bladder cancer.
  • To evaluate CDK6 as a prognostic biomarker and its association with immunotherapy response.

Main Methods

  • Bioinformatic analysis of public databases and retrospective case series.
  • Immunohistochemistry and functional annotation (gene function enrichment).
  • Analysis of tumor immune microenvironment and molecular subtypes.

Main Results

  • CDK6 expression is a significant prognostic marker in bladder cancer.
  • High CDK6 expression correlates with poor prognosis and diminished immunotherapy response.
  • CDK6 influences tumor immunity, metabolism, and cell cycle pathways, suppressing anti-tumor responses.

Conclusions

  • CDK6 serves as an independent biomarker for predicting bladder cancer prognosis and immunotherapy efficacy.
  • Targeting CDK6 presents a potential therapeutic strategy for bladder cancer.
  • Further research into CDK6's molecular mechanisms may unveil novel treatment approaches.

Keywords: